TY - JOUR
T1 - A deep look into the storm
T2 - Israeli multi-center experience of coronavirus disease 2019 (COVID-19) in patients with autoimmune inflammatory rheumatic diseases before and after vaccinations
AU - Kharouf, Fadi
AU - Eviatar, Tali
AU - Braun, Maya
AU - Pokroy-Shapira, Elisheva
AU - Brodavka, Michal
AU - Zloof, Yair
AU - Agmon-Levin, Nancy
AU - Toledano, Kochava
AU - Oren, Shirly
AU - Lidar, Merav
AU - Zisman, Devy
AU - Tavor, Yonit
AU - Amit-Vazina, Mirit
AU - Sabbah, Firas
AU - Breuer, Gabriel S.
AU - Dagan, Amir
AU - Beshara-Garzuzi, Rima
AU - Markovits, Doron
AU - Elias, Muna
AU - Feld, Joy
AU - Tayer-Shifman, Oshrat
AU - Gazitt, Tal
AU - Reitblatt, Tatiana
AU - Rubin, Limor
AU - Haddad, Amir
AU - Giryes, Sami
AU - Paran, Daphna
AU - Peleg, Hagit
AU - Molad, Yair
AU - Elkayam, Ori
AU - Mevorach, Dror
AU - Balbir-Gurman, Alexandra
AU - Braun-Moscovici, Yolanda
N1 - Publisher Copyright:
Copyright © 2023 Kharouf, Eviatar, Braun, Pokroy-Shapira, Brodavka, Zloof, Agmon-Levin, Toledano, Oren, Lidar, Zisman, Tavor, Amit-Vazina, Sabbah, Breuer, Dagan, Beshara-Garzuzi, Markovits, Elias, Feld, Tayer-Shifman, Gazitt, Reitblatt, Rubin, Haddad, Giryes, Paran, Peleg, Molad, Elkayam, Mevorach, Balbir-Gurman and Braun-Moscovici.
PY - 2023
Y1 - 2023
N2 - Objective: We aimed to characterize the course of COVID-19 in autoimmune inflammatory rheumatic disease (AIIRD) patients in Israel, taking into consideration several remarkable aspects, including the outcomes of the different outbreaks, the effect of vaccination campaigns, and AIIRD activity post-recovery. Methods: We established a national registry of AIIRD patients diagnosed with COVID-19, including demographic data, AIIRD diagnosis, duration and systemic involvement, comorbidities, date of COVID-19 diagnosis, clinical course, and dates of vaccinations. COVID-19 was diagnosed by a positive SARS-CoV-2 polymerase chain reaction. Results: Israel experienced 4 outbreaks of COVID-19 until 30.11.2021. The first three outbreaks (1.3.2020 – 30.4.2021) comprised 298 AIIRD patients. 64.9% had a mild disease and 24.2% had a severe course; 161 (53.3%) patients were hospitalized, 27 (8.9%) died. The 4th outbreak (delta variant), starting 6 months after the beginning of the vaccination campaign comprised 110 patients. Despite similar demographic and clinical characteristics, a smaller proportion of AIIRD patients had negative outcomes as compared to the first 3 outbreaks, with regards to severity (16 patients,14.5%), hospitalization (29 patients, 26.4%) and death (7 patients, 6.4%). COVID-19 did not seem to influence the AIIRD activity 1-3 months post-recovery. Conclusions: COVID-19 is more severe and has an increased mortality in active AIIRD patients with systemic involvement, older age and comorbidities. Vaccination with 3 doses of the mRNA vaccine against SARS-CoV-2 protected from severe COVID-19, hospitalization and death during the 4th outbreak. The pattern of spread of COVID-19 in AIIRD patients was similar to the general population.
AB - Objective: We aimed to characterize the course of COVID-19 in autoimmune inflammatory rheumatic disease (AIIRD) patients in Israel, taking into consideration several remarkable aspects, including the outcomes of the different outbreaks, the effect of vaccination campaigns, and AIIRD activity post-recovery. Methods: We established a national registry of AIIRD patients diagnosed with COVID-19, including demographic data, AIIRD diagnosis, duration and systemic involvement, comorbidities, date of COVID-19 diagnosis, clinical course, and dates of vaccinations. COVID-19 was diagnosed by a positive SARS-CoV-2 polymerase chain reaction. Results: Israel experienced 4 outbreaks of COVID-19 until 30.11.2021. The first three outbreaks (1.3.2020 – 30.4.2021) comprised 298 AIIRD patients. 64.9% had a mild disease and 24.2% had a severe course; 161 (53.3%) patients were hospitalized, 27 (8.9%) died. The 4th outbreak (delta variant), starting 6 months after the beginning of the vaccination campaign comprised 110 patients. Despite similar demographic and clinical characteristics, a smaller proportion of AIIRD patients had negative outcomes as compared to the first 3 outbreaks, with regards to severity (16 patients,14.5%), hospitalization (29 patients, 26.4%) and death (7 patients, 6.4%). COVID-19 did not seem to influence the AIIRD activity 1-3 months post-recovery. Conclusions: COVID-19 is more severe and has an increased mortality in active AIIRD patients with systemic involvement, older age and comorbidities. Vaccination with 3 doses of the mRNA vaccine against SARS-CoV-2 protected from severe COVID-19, hospitalization and death during the 4th outbreak. The pattern of spread of COVID-19 in AIIRD patients was similar to the general population.
KW - AIIRD
KW - COVID-19, coronavirus disease 2019
KW - SARS-CoV-2
KW - autoimmune inflammatory rheumatic disease
KW - outbreaks
KW - severe acute respiratory syndrome coronavirus-2
KW - vaccination
UR - http://www.scopus.com/inward/record.url?scp=85150885223&partnerID=8YFLogxK
U2 - 10.3389/fimmu.2023.1064839
DO - 10.3389/fimmu.2023.1064839
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 36993961
AN - SCOPUS:85150885223
SN - 1664-3224
VL - 14
JO - Frontiers in Immunology
JF - Frontiers in Immunology
M1 - 1064839
ER -